SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., a pharmaceutical company specializing in central nervous system disorders, has revealed a promising collaboration with Clearmind Medicine Inc., focusing on a ketamine-based therapy combination for mental health, addictions, and weight loss. Their joint research has led to the filing of thirteen patents for treatments combining SciSparc’s PEA compound with Clearmind’s psychedelic molecule MEAI. This novel approach aims to reduce dosage requirements and minimize side effects while maintaining therapeutic effectiveness.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
